Fibrocor, the Core of Fibrosis Therapeutics.
Nearly 45% of all deaths in the industrialized world are attributable to diseases of fibrosis. They include not only the pulmonary fibroses (IPF, ILD) but also liver cirrhosis, most forms of chronic kidney disease, and scleroderma.
Henderson, Rieder and Wynn. Fibrosis: from mechanisms to Medicines. Nature 2020, 587, pages 555–566
Fibrocor’s approach to drug discovery program centres on patient-derived tissue samples to identify and drug critical pathways in the fibrogenic process.
Our patient-derived target discovery platform leverages one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue, enabling the identification of novel disease targets and the development of a robust pipeline of first-in-class therapeutics.
In diseases of fibrosis, excessive scar tissue formation disrupts normal organ function leading to impairement and eventually failure. Recognizing the severity, and unmet need, Fibrocor Therapeutics confronts the challenges by combining its patient-derived target discovery platform with world-leading medicinal chemistry capabilities.
Poor Late-stage prognosis
Limited treatment options
Targeting Fibrosis with Patients at the Core
Patient-Derived Disease driven Insights at the Heart of Innovation:
One of our key differentiators comprises exclusive access to one of the world’s largest fibrosis tissue biobanks containing kidney, liver, and lung biopsies. These biobanks are connected to best-in-class longitudinal medical records, providing Fibrocor with invaluable patient information for research and development. Focused on this comprehensive data, we gained deep insights into the underlying mechanisms of fibrosis to make significant strides in the field. Our exceptional drug candidates have progressed seamlessly into the pre-clinical assessment, paving the way for transformative advancements in fibrosis treatment.
Longitudinal biobank samples correlated with fibrotic pathology, clinical outcome.
Single-cell and bulk RNAseq analysis for target discovery
Focus on novel tractable targets
Fibrosis Molecular pathways, genomic association and key biological insights.
Validation of key candidate compounds
Clinically relevant in vitro fibrosis assays and In vivo disease models.
Promising compounds with exceptional results
Best-in-class candidates (FIB991. FIB992 and FIB918) ready to progress to clinical phase.